Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
July 13, 2020 03:30 ET
|
Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
Arch Biopartners Closes Non-Brokered Private Placement
June 30, 2020 09:21 ET
|
Arch Biopartners
TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Arranges Non-Brokered Private Placement
June 24, 2020 08:41 ET
|
Arch Biopartners
TORONTO, June 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
June 16, 2020 10:48 ET
|
Arch Biopartners
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
June 08, 2020 07:00 ET
|
Arch Biopartners
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
June 02, 2020 07:00 ET
|
Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in...
Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update
May 08, 2020 08:05 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, May 08, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics,...
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
May 08, 2020 06:00 ET
|
Arch Biopartners
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
May 05, 2020 07:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BioStem Technologies Announces Corporate Update on Company Direction
April 29, 2020 12:35 ET
|
BioStem Technologies, Inc.
Pompano Beach, FL, April 29, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based...